The following section summarizes insights on SmartFinancial Inc's Capital Expenditures Margin:
United Therapeutics's latest twelve months net income to common excl extra items is 1.195 billion
United Therapeutics's net income to common excl extra items for fiscal years ending December 2020 to 2024 averaged 779.6 million.
United Therapeutics's operated at median net income to common excl extra items of 727.3 million from fiscal years ending December 2020 to 2024.
Looking back at the last 5 years, United Therapeutics's net income to common excl extra items peaked in December 2024 at 1.195 billion.
United Therapeutics's net income to common excl extra items hit its 5-year low in December 2021 of 475.8 million.
United Therapeutics's net income to common excl extra items decreased in 2021 (475.8 million, -7.6%) and increased in 2020 (514.8 million, -592.6%), 2022 (727.3 million, +52.9%), 2023 (984.8 million, +35.4%) and 2024 (1.195 billion, +21.4%).
Press space bar to start a drag.
When dragging you can use the arrow keys to move the item around and escape to cancel.
Some screen readers may require you to be in focus mode or to use your pass through key